Medical device go to market strategy.
Sold to a committee, not a buyer. Medical device sales runs through value analysis committees, group purchasing agreements and clinical evidence review. A CRM modelled on a single decision maker cannot represent any of it.
The surgeon wants it. The committee decides.
The clinical champion is enthusiastic and has no budget authority. Value analysis wants evidence, supply chain wants a contract vehicle, and finance wants a cost comparison. A pipeline built around the champion forecasts deals that cannot close.
Champion convinced. Committee has not met.
Medical devices — the committeeModelling how hospitals actually buy.
Value analysis as a stage
Committee submission, review cycle and decision modelled with real durations, because those cycles run on a calendar that has nothing to do with your quarter.
IDN and GPO hierarchy
Health systems, member facilities and purchasing agreements as a real account hierarchy. A contract at the system level changes what every facility beneath it can buy.
Clinical evidence as an asset
Which studies, outcomes and reference sites were sent to whom, tracked as engagement rather than living in a rep's personal folder.
The committee on the deal
Clinical champion, value analysis lead, supply chain, finance and infection control, with roles labelled, so single-threading is visible before it costs the deal.
Trials and evaluations
Product evaluations and clinical trials as their own pipeline with their own conversion rate, because they are the leading indicator of everything downstream.
Compliance boundaries
Interactions with clinicians carry transparency obligations, and patient data must not be anywhere near the CRM. Both designed in from the start.
Strategy that ships as a system.
Diagnose
Where revenue actually comes from today, read from the systems rather than from the deck — sources, cycle times, win rates and the segments that quietly carry the number.
Decide
Segment, offer, motion and pricing written as decisions with owners and dates attached, not as a framework with boxes to fill in later.
Instrument
The CRM, the routing, the definitions and the dashboards rebuilt so the plan is measurable the week it launches rather than the quarter after.
Run it with you
We operate the motion alongside your team until the number repeats, then hand it over with the documentation to keep it repeating.
Forecasting on the champion.
A deal marked ninety per cent because the surgeon is enthusiastic, when value analysis has not met and the GPO contract does not include you. Forecast on committee progress and contract vehicle, and the number stops being an optimism index.
What people ask before they commit.
Can HubSpot model IDN hierarchies?
Yes, with company hierarchies and custom objects for purchasing agreements. It needs designing deliberately, because the default company model is flat and hospital purchasing is not.
How do we forecast value analysis cycles?
By recording committee meeting calendars and historical cycle durations per account. They are more predictable than they feel once anybody starts writing them down.
What about transparency reporting?
Interactions and transfers of value need capturing in a way that supports your reporting obligations. We build the capture; your compliance team defines the requirement.
Does this apply to diagnostics and life sciences?
Largely yes. The committee structure, contract vehicles and evidence requirements are similar, and we work across biotech and health care too.
How long does it take?
Ten to sixteen weeks. Account hierarchy design and the committee model are the substantial pieces.
Where people go from here.
Forecast on the committee.
Tell us what you are running
What the system does today, where it breaks, and when it has to work. An engineer reads it — you get an answer inside one business day, not a sequence.